Home›Stock Screener›Strides Pharma Science›Quarterly Results

Strides Pharma Science Quarterly Results

Latest Quarter Net Profit
₹129 Cr
QMar 2026
Quarterly Results

Strides Pharma Science quarterly results. In Mar 2026, Strides Pharma Science (STAR) reported revenue ₹1,333 Cr and net profit ₹129 Cr — revenue +10.5% YoY. For annual financials, live price and key ratios, visit Strides Pharma Science screener.

STAR Quarterly Results — Revenue, Profit & EPS Highlights

Strides Pharma Science latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Check Strides Pharma Science market worth to track the company's total market size over time.

  • Revenue of ₹1,333 Cr in Mar 2026 (-0.1% vs Jun 2026, +10.5% vs Mar 2025)
  • Net Profit of ₹129 Cr in Mar 2026 (-22.3% vs Jun 2026, +50.0% vs Mar 2025)
  • EBITDA of ₹243 Cr in Mar 2026 (-18.2% vs Jun 2026)
  • Operating Margin of 18.0% in Mar 2026 (+0.0pp vs Jun 2026)
  • Earnings Per Share of ₹13.77 in Mar 2026 (-19.1% vs Jun 2026)

Strides Pharma Science Quarterly Results — Revenue, EBITDA, Net Profit & EPS

STAR quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Mar 2026 Jun 2026 Sept 2025 Mar 2025 Jun 2025 QoQ YoY
Revenue (₹ Cr) 1,333 1,334 1,248 1,206 1,128 -0.1% 10.5%
Net Profit (₹ Cr) 129 166 132 86 106 - -
EBITDA (₹ Cr) 243 297 249 206 218 - -
EPS (₹) 13.77 17.02 13.84 8.92 10.81 - -
Operating Margin (%) 18.0% 18.0% 18.0% 16.0% 19.0% - -

STAR Share Price Trend — 1-Year Movement Across Quarterly Results

Strides Pharma Science 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Review Strides Pharma Science P/E valuation to evaluate earnings-based valuation against sector peers.

Profitability Ratios

Profit Margin 9.7%
EBITDA Margin 18.2%
Operating Margin 18.0%
ROE (Annual) 16.4%

Balance Sheet Highlights

Total Assets ₹6,927 Cr
Total Equity ₹3,149 Cr
Current Assets ₹3,613 Cr
Current Liabilities ₹882 Cr

Cash Flow Analysis

Operating Cash Flow ₹703 Cr
Investing Cash Flow ₹-173 Cr
Financing Cash Flow ₹-453 Cr
Net Cash Flow ₹76 Cr

Current Market Data

Current Price ₹1086.70
Exchange NSE
Last Updated Oct 05, 2026

Revenue Trend (₹ Cr)

Mar 2025 1,206
Sept 2025 1,248
Jun 2026 1,334
Mar 2026 1,333

Net Profit Trend (₹ Cr)

Mar 2025 86
Sept 2025 132
Jun 2026 166
Mar 2026 129

Operating Margin Trend (%)

Mar 2025 16.0%
Sept 2025 18.0%
Jun 2026 18.0%
Mar 2026 18.0%

STAR vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Strides Pharma Science latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Mar 2026 		₹432,120.23 Cr 1779.7 15,018 2,710 -5.6% - 18.0% 157.5
Divis Laboratories
Mar 2026 		₹253,522.49 Cr 9196.0 2,986 751 -5.0% - 25.2% 324.8
Torrent Pharmaceuti…
Mar 2026 		₹188,719.51 Cr 4772.0 4,111 364 +27.7% +42.2% 8.9% 414.6
Zydus Life Science
Mar 2026 		₹113,615.69 Cr 1139.0 7,569 1,341 -4.3% - 17.7% 90.0
Cipla
Mar 2026 		₹108,576.18 Cr 1335.5 6,612 543 -9.3% - 8.2% 194.4
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data

QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores